Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
Hossam M. Ali et al · Nature Publishing Group · 2026
Acceso al recurso
Entrá al contenido desde la opción principal o elegí otra fuente disponible.
Acceso abierto disponible
Cómo citar
Elegí el formato que necesitás y copiá la referencia al portapapeles.
APA 7
al, H. M. A. E. (2026). Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort. https://doi.org/10.1038/s41408-026-01512-z
MLA
al, Hossam M. Ali et. "Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort." 2026. https://doi.org/10.1038/s41408-026-01512-z.
Chicago
al, Hossam M. Ali et. 2026. "Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.". https://doi.org/10.1038/s41408-026-01512-z.
Harvard
al, H. M. A. E. 2026, Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort, Nature Publishing Group, available at: https://doi.org/10.1038/s41408-026-01512-z [Accessed 29 Jun. 2026].
Detalles del recurso
Información bibliográfica útil para confirmar que se trata del material correcto.
- Título
- Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
- Autor / colaboradores
- Hossam M. Ali et al
- Editorial
- Nature Publishing Group
- Año de publicación
- 2026
- ISSN
- 2044-5385
- ISSN
- 2044-5385
- Idioma
- eng